FDA Policy On Financial Conflicts Of Public Speakers At Advisory Panels Unchanged
This article was originally published in The Pink Sheet Daily
In final guidance, the agency has rejected calls by the advocacy group Public Citizen to allow committee members to question open public hearing speakers on their finances.
You may also be interested in...
Revelations about speaking and consulting agreements between two FDA advisory committee members, Avandia maker GlaxoSmithKline and Actos maker Takeda, suggest the agency may need to further refine its conflict-of-interest screening procedures to ensure a public perception that it is receiving independent advice from outside experts
There may be more at stake for FDA, and the pharmaceutical industry in general, in how the advisory committees interpret the RECORD trial than there is for Avandia itself.
FDA should permit advisory committee members and voting consultants to question open public hearing speakers about their potential conflicts of interest during advisory committee meetings, according to the consumer advocacy group Public Citizen